Table 1 Patients characteristics at inclusion

From: RADTHYR: an open-label, single-arm, prospective multicenter phase II trial of Radium-223 for the treatment of bone metastases from radioactive iodine refractory differentiated thyroid cancer

Median age at inclusion (years) 74 [46–88]
Sex 4 males (40%) / 6 women (60%)
Histology
Papillary 5 (50%)
Follicular 2 (20%)
Hurthle cell 1 (10%)
Poorly differentiated 2 (20%)
ECOG score
0 5 (50%)
1 4 (40%)
2 1 (10%)
Median time since total thyroidectomy (years) 7 [1–16]
Median delay since discovery of 1st bone metastases (years) 6 [0–17]
Median time since last 131I treatment (years) 3 [0–10]
Median number of 131I treatments 4 [2–8]
Median total cumulated activity (GBq) 15 [7.4–35.6]
Treatment of bone metastases  
External radiation 9 (90%)
Surgery 8 (80%)
Cementoplasty 5 (30%)
Cryoablation 2 (20%)
Bisphosphonates 3 (30%)
Rank ligand inhibitors 2 (20%)
Presence of visceral metastases at inclusion  
Neck (lymph nodes) 1 (10%)
Lung 5 (50%)
Localization of bone metastases
Axial 10 (100%)
Peripheral skeleton 3 (30%)
Number of patients according to target lesion type
Only lytic 5 (50%)
Only mixed 1 (10%
Lytic + mixed 2 (20%)
Lytic + sclerotic + mixed 2 (20%)
Patients with negative Ab anti Tg 7
Median Tg levels at baseline (ng/ml) 14.645 [486–23.200]
Patients with positive Ab anti Tg 3
Median value of Abanti Tg (> 4 UI/mL) 25 [8–25]
Median ALP levels at baseline (UI/L) 62 [48–122]
Median b-ALP levels at baseline (U/L) 8 [0–22]
  1. The results are reported by median (range)
  2. ECOG Eastern Cooperative Oncology Group, Tg thyroglobulin, ALP alkaline phosphatase, Ab antibodies